BiotechTube

ZW25

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Endometrial Cancer

Conditions

Endometrial Cancer, Carcinosarcoma

Trial Timeline

Aug 12, 2020 → Mar 8, 2024

NCT ID
NCT04513665

About ZW25

ZW25 is a phase 2 stage product being developed by Zymeworks for Endometrial Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT04513665. Target conditions include Endometrial Cancer, Carcinosarcoma.

What happened to similar drugs?

0 of 20 similar drugs in Endometrial Cancer were approved

Approved (0) Terminated (0) Active (20)
🔄Trastuzumab deruxtecan + Rilvegostomig + Pembrolizumab + Carboplatin + Paclitaxel + DocetaxelDaiichi SankyoPhase 3
🔄Trastuzumab Deruxtecan + ChemotherapyDaiichi SankyoPhase 3
🔄Lenvatinib + Pembrolizumab + Paclitaxel + CarboplatinEisaiPhase 3
🔄Pembrolizumab + Lenvatinib + Paclitaxel + DoxorubicinEisaiPhase 3
🔄Lenvatinib + Pembrolizumab + Paclitaxel + CarboplatinEisaiPhase 3
🔄Puxitatug Samrotecan + Doxorubicin + PaclitaxelAstraZenecaPhase 3
🔄olaparib + durvalumab + durvalumab placebo + olaparib placebo + Carboplatin + PaclitaxelAstraZenecaPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04513665Phase 2Completed

Competing Products

20 competing products in Endometrial Cancer

See all competitors
ProductCompanyStageHype Score
Atezolizumab - 28 Day Cycle + Bevacizumab + Ipatasertib + Talazoparib + Trastuzumab emtansine + Tiragolumab + Atezolizumab - 21 Day Cycle + Inavolisib + Letrozole + Giredestrant + AbemaciclibEli LillyPhase 1/2
39
ACR-368 + GemcitabineAcrivon TherapeuticsPhase 2
32
Sodium Cridanimod + progestin therapyXenetic BiosciencesPhase 2
17
Letrozole + Abemaciclib + LY3023414 + Metformin + Zotatifin + GedatolisibeFFECTOR TherapeuticsPhase 2
32
Trastuzumab deruxtecanDaiichi SankyoPhase 2
39
Trastuzumab deruxtecan + Rilvegostomig + Pembrolizumab + Carboplatin + Paclitaxel + DocetaxelDaiichi SankyoPhase 3
47
Trastuzumab Deruxtecan + ChemotherapyDaiichi SankyoPhase 3
47
Datopotamab deruxtecan (Dato-DXd) + Capecitabine + 5-Fluorouracil + Volrustomig + Carboplatin + Bevacizumab + Rilvegostomig + Prednisone/ prednisolone + CisplatinDaiichi SankyoPhase 2
42
Trastuzumab deruxtecanDaiichi SankyoPhase 2
42
Enfortumab VedotinAstellas PharmaPhase 2
42
Lenvatinib + Pembrolizumab + Paclitaxel + CarboplatinEisaiPhase 3
40
LenvatinibEisaiPhase 2
35
Pembrolizumab + Lenvatinib + Paclitaxel + DoxorubicinEisaiPhase 3
40
Lenvatinib + Pembrolizumab + Paclitaxel + CarboplatinEisaiPhase 3
40
E7386 + Lenvatinib + Doxorubicin + PaclitaxelEisaiPhase 1/2
36
Abemaciclib + LetrozoleEli LillyPhase 2
39
Abemaciclib + Anastrozole + LetrozoleEli LillyPhase 2
42
LY3023414Eli LillyPhase 2
35
arzoxifene hydrochlorideEli LillyPhase 2
35
Abemaciclib + Letrozole + PembrolizumabEli LillyPhase 2
42